SciClone set for US$12.8 million SEC foreign bribery settlement

SciClone Pharmaceuticals has agreed in principle to pay US$12.8 million to settle FCPA charges brought by the US Securities and Exchange Commission over conduct in China, the company said in a filing on 10 August.

Unlock unlimited access to all Global Investigations Review content